Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation

Summary

There are three different diagnostic score systems for disseminated intravascular coagulation (DIC) established by the Japanese Ministry Health and Welfare (JMHW), the International Society on Thrombosis and Haemostasis (ISTH) and the Japanese Association for Acute Medicine (JAAM). The JMHW criteria are still used in Japan. In the present study, all three diagnostic criteria were used to prospectively evaluate 413 patients with different underlying diseases of DIC who were treated at the Mie University Hospital (JMHW, n= 166; ISTH, n=143; JAAM, n=291). The odds ratio (95% confidence interval) for death was 1.88 (1.22 – 2.90) in JMHW, 2.55 (1.65 – 3.95) in ISHT and 1.99 (1.19 – 3.32) in JAAM. The platelet count, prothrombin time, fibrin and fibri-nogen degradation products and fibrinogen were significantly important for diagnosis of DIC by all three diagnostic criteria. Haemostatic molecular markers were significantly high in all patients and were useful for the diagnosis of DIC. The JAAM diagnostic criteria displayed a high sensitivity for DIC and the ISTH overt-DIC diagnostic criteria displayed a high specificity for DIC. All three diagnostic criteria for DIC were related to a poor patient outcome.

Keywords

DIC - Japanese Ministry Health and Welfare - ISTH - haemostatic markers - mortality - resolution rate

• References

• 1 Levi M. et al. Disseminated intravascular coagulation. Thromb Haemost 1999; 82: 695-705.
• 2 Kushimoto S. et al. Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma. Thromb Haemost 2008; 100: 1099-1105.
• 3 Taylor Jr FB. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation – On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001; 86: 1327-1330.
• 4 Wada H. Disseminated intravascular coagulation. Clin Chim Acta 2004; 344: 13-21.
• 5 Warren BL. et al. High-dose antithrombin in severe sepsis. A randomized controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
• 6 Bernard GR. et al. Efficacy and safety of recombinant human protein C for severe sepsis. N Engl J Med 2001; 08: 699-709.
• 7 Abraham E. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 2003; 290: 238-247.
• 8 Kobayashi N. et al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol 1983; 49: 265-275.
• 9 Gando S. et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group.. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34: 625-631.
• 10 Wada H. et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995; 74: 848-852.
• 11 Wada H. et al. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost 1998; 24: 293-297.
• 12 Egi M. et al. Non-overt disseminated intravascular coagulation scoring for critically ill patients: The impact of antithrombin levels. Thromb Haemost 2009; 101: 696-705.
• 13 Solano C. et al. Comparison of the 1999 Sapporo and 2006 revised criteria for the classification of the antiphospholipid syndrome. Clin Exp Rheumatol. 2009; 27: 914-919.
• 14 Vincent JL. et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intens Care Med 1996; 22: 707-710.
• 15 Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). J Am Med Assoc 1992; 268: 3452-3455.
• 16 Wada H. et al. Comparison of the responses of global tests of coagulation with molecular markers of neutrophil, endothelial, and hemostatic system perturbation in the baboon model of E. coli sepsis – Toward a distinct between uncompensated overt DIC and compensated non-overt DIC. Thromb Haemost 2001; 86: 1489-1494.
• 17 Asakura H. et al. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 2001; 67: 170-175.
• 18 Gando S. et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008; 36: 145-150.
• 19 Wada H, Gabazza EC, Asakura H. et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Haemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt-DIC. Am J Hematol 2003; 74: 17-22.
• 20 Wada H. et al. Diagnosis of disseminated intravascular coagulation by hemostatic molecular markers. Semin Thromb Hemost 2000; 26: 17-22.
• 21 Kienast J. et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006; 41: 90-97.
• 22 Wada H. et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1998; 58: 189-194.
• 23 Kinasewitz GT. et al. Prognostic value of a simple evolving disseminated intravascular coagulation score in patients with severe sepsis. Crit Care Med 2005; 33: 2214-2221.